Genclis is a biotechnology company that specializes in the development of RNA-derived therapeutics, leveraging a unique mechanism known as Transcription Infidelity (TI). This innovative technology leads to the creation of mRNA with gaps, resulting in the production of TI proteins that exhibit specific immunological properties. The company aims to revolutionize immunology by exploring the implications of TI in various therapeutic areas, including allergies, severe COVID-19, Type I diabetes, and neurodegenerative diseases like Lou Gehrig’s disease. Genclis is committed to advancing its drug development pipeline through rigorous preclinical studies, ensuring that its therapeutic solutions are both effective and reliable.

The company emphasizes a strong scientific foundation, with a team of skilled professionals dedicated to understanding and manipulating immune responses. Genclis's approach involves eliciting, enhancing, or modulating antibody responses to improve patient outcomes. By focusing on a robust data-driven strategy, Genclis aims to de-risk its therapeutic innovations while maintaining a steady and sustainable business model. The company also values collaboration with biopharma, laboratories, and clinicians to enhance the accuracy of diagnoses and the effectiveness of treatments, ultimately prioritizing patient care in its mission.

France

GENCLIS SA is a privately-held French Biotechnology that discovered a unique biological mechanism referred as to Transcription Infidelity (TI). 
Transcription Infidelity is a newly discovered and patented mechanism that incresases RNA-DNA sequence divergences (RDD). TI can lead to base substitutions, insertions and deletions. The latter cause translational frameshifts that have important consequences in determining protein immunogenicity. Genclis currently focuses on defining the effects of TI proteins translated from gapped RNA on normal and pathological humoral immunity.

Genclis

Company Details